Novartis launches direct-to-patient platform in US market

Swiss pharmaceutical giant Novartis is set to revolutionize drug distribution in the United States with the launch of its innovative direct-to-patient (DTP) platform. The initiative, announced on Monday, marks a significant shift in how prescription medications are delivered to American consumers. The platform will initially feature Cosentyx, the company's bestselling psoriasis treatment, offering unprecedented pricing transparency and accessibility to patients.

The direct-to-patient platform, scheduled to launch on November 1, 2025, will offer Cosentyx at a remarkable 55% discount compared to its list price. This innovative approach allows patients with valid prescriptions to purchase the medication directly, bypassing traditional distribution channels. The platform represents Novartis' response to ongoing concerns about drug pricing transparency and accessibility in the US market. The company plans to extend this model to other medications in its portfolio, potentially reshaping pharmaceutical distribution practices.

This strategic move by Novartis could significantly disrupt the traditional pharmaceutical distribution model in the United States. By offering Cosentyx, its top-selling US product, through a direct channel, Novartis is addressing the growing demand for price transparency and reduced healthcare costs. The initiative aligns with broader industry trends toward patient-centric healthcare solutions and could potentially influence other pharmaceutical companies to adopt similar approaches.

The launch of this platform demonstrates Switzerland's continued leadership in pharmaceutical innovation and its commitment to addressing global healthcare challenges. Novartis, as a Swiss company, brings its reputation for precision and quality to the US market while adapting to local healthcare needs. This initiative reflects the company's understanding of the unique challenges within the US healthcare system and its ability to develop market-specific solutions while maintaining Swiss standards of excellence.